Medical Safety of Ivermectin
Descotes, J., ImmunoSafe Consultance (Preprint)
Descotes, Medical Safety of Ivermectin, , J., ImmunoSafe Consultance (Preprint)
Safety analysis of >350 articles showing that ivermectin has an excellent safety profile. The author notes that "no severe adverse event has been reported in dozens of completed or ongoing studies involving thousands of participants worldwide to evaluate the efficacy of ivermectin against COVID-19".
Descotes et al., 5 Mar 2021, preprint, 1 author.
Abstract: Jacques Descotes MD, PharmD, PhD
Professor Emeritus, Claude Bernard University of Lyon
Fellow, US Academy of Toxicological Sciences
Eurotox Registered Toxicologist
IMMUNOSAFE CONSULTANCE
120 Chemin des Bouleaux
38480 Saint Jean d’Avelanne, France
Tel. +33 (0)616 96 35 97
E-mail = descotes@me.com
EXPERT REVIEW REPORT
MEDICAL SAFETY OF IVERMECTIN
As per the request of MedinCell SA (France), I the undersigned certify to have perused the publicly
available information relevant to conduct an extensive analysis of ivermectin safety in human beings.
The aim of the present review is to propose an independent, evaluative judgement of this information
which includes original scientific publications and literature reviews, case reports, and any other source
provided it can be undisputedly tracked down and freely accessed. The author personally collected and
reviewed all the cited information from the beginning of September 2020 to the end of February 2021.
Table of Contents
I.
II.
III.
IV.
Executive summary ........................................................................................................ 2
Introduction ..................................................................................................................... 5
Summary of main nonclinical toxicity findings ................................................................ 9
Human adverse events and ivermectin exposure......................................................... 19
• Adverse events in clinical trials and following medical prescription of ivermectin .... 19
• Acute poisonings and accidental overdoses ............................................................ 24
V. Risk factors .................................................................................................................. 26
• Clinical safety of ivermectin in infants and children ................................................ 26
• Clinical safety of ivermectin in pregnant and breast-feeding women ...................... 26
• Clinical safety of ivermectin in the elderly ............................................................... 27
• Comorbidities ........................................................................................................... 27
• Drug associations .................................................................................................... 29
VI. Discussion ................................................................................................................... 31
VII. Conclusion .................................................................................................................... 33
VIII. References .................................................................................................................. 34
IX. Author's resume ........................................................................................................... 45
I. EXECUTIVE SUMMARY
Ivermectin was first approved as a human medicine in 1987. In addition to 40 years of
extensive use as a veterinary medicine, it has been prescribed to hundreds of millions
of human beings worldwide to prevent or treat a variety of parasitic diseases. Recently,
the anti-SARS-cov-2 activity of ivermectin became the focus of numerous experimental
studies and clinical trials, the results and interpretation of which generated a vigorous
and still ongoing debate to establish how effective ivermectin is or could be against
COVID-19. Drug approvals by regulatory..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit